Hasegawa Mina, Ide Mika, Kuwamura Mitsuru, Yamate Jyoji, Takenaka Shigeo
J Toxicol Pathol. 2010 Jun;23(2):67-74. doi: 10.1293/tox.23.67. Epub 2010 Jun 30.
Detection of the toxicity of a candidate compound at an early stage of drug development is an emerging area of interest. It is difficult to determine all of the effects of metabolism of a compound using traditional approaches such as histopathology and serum biochemistry. The goal of a metabolomics approach is to determine all metabolites in a living system, with the potential to detect and identify biomarkers involved in toxicity onset. Here, we summarize the metabolic fingerprints for detection and identification of metabolic changes and biomarkers related to drug-induced toxicity using Fourier transform ion cyclotron resonance mass spectrometry (FT-ICR MS).
在药物研发的早期阶段检测候选化合物的毒性是一个新兴的研究领域。使用传统方法如组织病理学和血清生物化学来确定化合物代谢的所有影响是困难的。代谢组学方法的目标是确定生物系统中的所有代谢物，有可能检测和识别与毒性发生相关的生物标志物。在此，我们总结了使用傅里叶变换离子回旋共振质谱（FT-ICR MS）检测和识别与药物诱导毒性相关的代谢变化和生物标志物的代谢指纹图谱。
